Elysium Therapeutics is advancing a novel therapeutic approach to address opioid overdose through its Synthetic Opioid Overdose Prevention and Reversal (SOOPR) program. The investigational longer-lasting rescue agent, including the candidate zelpultide alfa, aims to overcome limitations of current treatments like naloxone and nalmefene, which often fail due to fentanyl rebound or re-narcotization. A planned multinational Phase III clinical trial will enroll over 300 pre-term neonates to assess its efficacy against bronchopulmonary dysplasia, while expansion of trial sites is underway globally. This work targets a critical unmet need in opioid overdose management and preterm neonate lung disease.